Although this is an example of the removal a transcription factor in order to acquire a higher level of gene expression, it does give an insight into the possibility in modulating the level of the Oct-1 transcription factor to influence FXN gene expression as a potential clinical therapy for FRDA. Here, FXN is linked to Friedreich ataxia.